E
Pharmala Biotech Holdings Inc. MDMA
CNSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

02/28/2025 11/30/2024
Revenue 144.12% 8.59%
Total Other Revenue -- --
Total Revenue 144.12% 8.59%
Cost of Revenue -- --
Gross Profit 128.06% -71.69%
SG&A Expenses 82.98% 26.48%
Depreciation & Amortization -5.58% 28.74%
Other Operating Expenses -- --
Total Operating Expenses 84.64% 92.88%
Operating Income -76.61% -115.55%
Income Before Tax -62.65% -112.64%
Income Tax Expenses -- --
Earnings from Continuing Operations -62.65% -112.64%
Earnings from Discontinued Operations -- --
Extraordinary Item & Accounting Change -- --
Minority Interest in Earnings -- --
Net Income -62.65% -112.64%
EBIT -76.61% -115.55%
EBITDA -79.33% -113.93%
EPS Basic -43.59% -116.67%
Normalized Basic EPS -52.17% -109.09%
EPS Diluted -43.59% -116.67%
Normalized Diluted EPS -52.17% -109.09%
Average Basic Shares Outstanding 14.89% -3.47%
Average Diluted Shares Outstanding 14.89% -3.47%
Dividend Per Share -- --
Payout Ratio -- --